MedTrace Logo

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

NCT00403455 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.

Conditions

Interventions

DRUG

Paroxetine

SSRI

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Zhewu Wang, MD · Ralph H. Johnson VA Medical Center, Charleston, SC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403455 on ClinicalTrials.gov